Second-line therapy for castrate-resistant prostate cancer: A literature review

Asia-Pacific Journal of Clinical Oncology

Volumn 7, Issue 3, 2011, Pages 212-223

  Kao, S C H ^a,b   Hovey, E ^c,d   Marx, G ^b,e  

^a ANZAC Research Institute   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e SYDNEY ADVENTIST HOSPITAL   (Australia)

Author keywords

Castrate resistant prostate cancer; Cytotoxic; Hormone therapy; Immunotherapy; Second line chemotherapy

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE ACETATE; ACID PHOSPHATASE PROSTATE ISOENZYME; AFLIBERCEPT; ALKALINE PHOSPHATASE; AMINOGLUTETHIMIDE; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CABAZITAXEL; CALCITRIOL; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; ESTRAMUSTINE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROCORTISONE; IPILIMUMAB; IXABEPILONE; LENALIDOMIDE; MITOXANTRONE; NAVELBINE; ORTERONEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROVENGE; SATRAPLATIN; THALIDOMIDE; VASCULOTROPIN;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANALGESIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; BONE DISEASE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CALCIUM HOMEOSTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL ACTIVITY; CELL COUNT; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL DIFFERENTIATION; CELL GROWTH; COLITIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DEHYDRATION; DENDRITIC CELL; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ACTIVITY; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG POTENCY; DRUG RECHALLENGE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FLU LIKE SYNDROME; FLUID RETENTION; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; GENE OVEREXPRESSION; HEALTH CARE QUALITY; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOPHYSITIS; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; IN VIVO STUDY; INFECTION; LEUKAPHERESIS; LEUKOPENIA; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; MITOSIS INHIBITION; MONOTHERAPY; MORBIDITY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NEOVASCULARIZATION (PATHOLOGY); NEUTROPENIA; NONHUMAN; OPEN STUDY; OVERALL SURVIVAL; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; T LYMPHOCYTE; THROMBOCYTOPENIA; TUMOR CELL; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOTHERAPY; MALE; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RETREATMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 80052226723     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2011.01421.x     Document Type: Review

References (63)

1. Heidenreich A, Aus G, Abbou CC etal. Guidelines on prostate cancer. Eur Assoc Urol 2007; 6: 683-8.
2. Carden CP, Rosenthal MA. Immediate versus delayed chemotherapy in patients with asymptomatic incurable metastatic cancer. Asia Pac J Clin Oncol 2008; 3: 187-98.
3. Petrylak DP, Tangen CM, Hussain MH etal. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20.
4. Tannock IF, de Wit R, Berry WR etal. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12.
5. Kantoff PW, Halabi S, Conaway M etal. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999; 17: 2506-13.
6. Tannock I, Osoba D, Stockler MR etal. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomised trial with palliative end points. J Clin Oncol 1996; 14: 1756-64.
7. Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 2002; 168: 2439-43.
8. Berthold DR, Pong GR, Soban F etal. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26: 242-5.
9. de Bono J, Oudard S, Ozguroglu M etal. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-54.
10. de Bono J, Logothetis C, Fizazi K etal. Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after docetaxel-based chemotherapy (chemo): results of COU-AA-301. A randomized double-blind placebo-controlled phase 3 study. (Abstract LBA5). Ann Oncol 2010; 21: viii3.
11. Kantoff P, Higano C, Shore N etal. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-22.
12. Scher H, Logothetis C, Molina A etal. Improved survival outcomes in clinically relevant paitent subgroups from COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-based chemotherapy. J Clin Oncol 2011; 29: Abstract 4.
13. Beekman K, Fleming M, Scher H etal. Second-line chemotherapy for prostate cancer: patient characteristics and survival. Clin Prostate Cancer 2005; 4: 86-90.
14. Oh WK, Manola J, Babcic V etal. Response to second line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. Uronlogy 2006; 67: 1235-40.
15. Michels J, Montemurro T, Murray N etal. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer. Does sequence matter? Cancer 2006; 106: 1041-6.
16. Joshua A, Nordman I, Venkataswaran R, Clarke S, Stockler M, Boyer M. Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer. Int Med J 2005; 35: 468-72.
17. Saad F, Ruether D, Ernst S etal. The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone. BJU Int 2008; 102: 551-5.
18. Berthold DR, Pond GR, de Wit R, Eisenberger M, Tannock IF. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 2008; 19: 1749-53.
19. Jankovic B, Beardsley E, Chi K. Rechallenge with docetaxel as second-line chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) after previous docetaxel: a population based analysis. Genitourin Cancers Symp 2008; Abstract 196.
20. Eymard J, Oudard S, Gravis G etal. Second-line chemotherapy with docetaxel (D) in men treated with docetaxel-based regimen for metastatic hormone-refractory prostate cancer (mHRPC). ASCO Prostate Cancer Symp 2007; Abstract 249.
21. Ansari J, Hussain S, Zarkar A, Tanguay J, Bliss J, Glaholm J. Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience. Oncol Rep 2008; 20: 891-6.
22. Gernone A, Troccoli G, Pagliarulo V, Pagliarulo A. Retreatment with docetaxel in metastatic castration-resistant prostate cancer (CRPC). Genitourin Cancers Symp 2010; Abstract 143.
23. Winquist E, Waldron T, Berry S, Ernst SD, Hotte S, Lukka H. Non-hormonal systemic therapy in men with hormonerefractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group. BMC Cancer 2006; 6. DOI.10.1.1186/1471-2407-6-112.
24. Abratt RP, Brune D, Dimopoulos MA etal. Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer. Ann Oncol 2004; 15: 1613-21.
25. Carles GJ, Bastus PR, Martin-Broto J etal. A phase II study of vinorelbine and estramustine in patients with hormone-resistant prostate cancer. Clin Transl Oncol 2005; 7: 66-73.
26. Borrega P, Velasco A, Bolanos M etal. Phase II trial of vinorelbine and estramustine in the treatment of metastatic hormone-resistant prostate cancer. Urol Oncol 2004; 22: 32-5.
27. Smith MR, Kaufman D, Oh W etal. Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study. Cancer 2000; 89: 1824-8.
28. Seidman AD, Scher HI, Petrylak D etal. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J Urol 1992; 147: 931-4.
29. Nakabayashi M, Ling J, Xie W etal. Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer. Cancer J 2007; 13: 125-9.
30. Glode LM, Barqawi A, Crighton F etal. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer 2003; 98: 1643-8.
31. Kao S, Hovey E. Low dose cyclophosphamide in heavily pre-treated metastatic hormone refractory prostate cancer. A case series of 12 patients. Asia Pac J Clin Oncol 2007; 3: A64.
32. Rosenberg JE, Weinberg VK, Kelly WK etal. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007; 110: 556-63.
33. Ross R, Beer T, Jacobus S etal. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer 2008; 112: 521-6.
34. Sartor AO, Petrylak D, Witjes JA etal. Satraplatin in patients with advanced hormone-refractory prostate cancer (HRPC): overall survival (OS) results from the phase III satraplatin and prednisone against refractory cancer (SPARC) trial. J Clin Oncol 2008; 26: Abstract 5003.
35. Shelley M, Harrison C, Coles B etal. Chemotherapy for hormone refractory prostate cancer. Cochrane Library, CD005247, 1, 2007.
36. Loening SA, Scott WW, DeKernion J etal. A comparison of hydroxyurea, methyl-chloroethyl-cyclohexy-nitrosourea and cyclophosphamide in patients with advanced carcinoma of the prostate. J Urol 1981; 125: 812-16.
37. Chlebowski RT, Hestorff R, Sardoff L etal. Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer: a randomized trial. Cancer 1978; 42: 2546-52.
38. Saxman S, Ansari R, Drasga R etal. Phase III trial of cyclophosphamide versus cyclophosphamide, doxorubicin, and methotrexate in hormone-refractory prostatic cancer. Cancer 1992; 70: 2488-92.
39. Galsky MD, Small EJ, Oh WK etal. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 2005; 23: 1439-46.
40. Oh WK, Tay MH, Huang J. Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer? Cancer 2007; 109: 477-86.
41. Petrylak DP, Sartor O, Witjes F etal. A phase III, randomized, double-blind trial of satraplatin and prednisone versus placebo and prednisone for patients with hormone refractory prostate cancer (HRPC). Prostate Cancer Symp 2007; Abstract 145.
42. Sternberg CN, Petrylak D, Witjes F etal. Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: results of a randomized phase III trial. J Clin Oncol 2007; 25: 5019 (Abstract 5019).
43. Skowronski R, Peehl D, Feldman D. Vitamin D and prostate cancer: 1, 25 dihyroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993; 132: 1952-60.
44. Barreto A, Schwartz G, Woodruff R, Cramer S. 25-Hydroxyvitamin D3, the prohormone of 1, 25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiol Biomarkers Prev 2000; 9: 265-70.
45. Banach-Petrosky W, Ouyang X, Gao H etal. Vitamin D inhibits the formation of prostatic intraepithelial neoplasia in Nkx3.1; Pten mutant mice. Clin Cancer Res 2006; 12: 5895-901.
46. Getzenberg RH, Light BW, Lapco PE etal. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 1997; 50: 999-1006.
47. Beer TM, Ryan CW, Venner PM etal. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 2007; 25: 669-74.
48. Lassi K, Dawson NA. Emerging therapies in castrate-resistant prostate cancer. Curr Opin Oncol. 2009; 21: 260-5.
49. Petrylak DP. New paradigms for advanced prostate cancer. Rev Urol 2007; 9: S3-12.
50. Figg WD, Dahut W, Duray P etal. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 2001; 7: 1888-93.
51. Retter AS, Ando DL, Price JL etal. Follow-up analysis of a randomized phase II study of docetaxel and thalidomide in androgen-independent prostate cancer. Updated survival and CYP2C19 mutation status. ASCO Prostate Cancer Symp 2005; Abstract 265.
52. Marx G, Pavlakis N, McCowatt S etal. ProTat: a phase II trial of docetaxel (D), prednisone (P) and thalidomide (T) in patients with androgen-independent prostate cancer (AIPC). J Clin Oncol 2005; 23: Abstract 4672.
53. Moss RA, Mohile SG, Shelton G, Melia J, Petrylak DP. Phase I open-label study using lenalidomide and docetaxel in androgen independent prostate cancer (AIPC). Proc ASCO Prostate Cancer Symp 2007; Abstract 89.
54. Di Lorenzo G, Figg W, Fossa S etal. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refratory prostate cancer: a phase 2 study. Eur Urol 2008; 54: 1089-98.
55. Picus J, Halabi S, Rini B etal. The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): initial results of CALGB 90006. J Clin Oncol 2003; 22: 393s (Abstract 1578).
56. Kelly W, Halabi S, Carducci M etal. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401. J Clin Oncol 2010; 28: 344s (Abstract LBA4511).
57. Tollefson M, Karnes R, Thompson R etal. A randomized phase II study of ipilimumab with androgen ablation compared with androgen ablation alone in patients with advanced prostate cancer. Genitourin Cancer Symp 2010; Abstract 168.
58. Scher H, Beer T, Higano C etal. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375: 1437-46.
59. Dreicer R, Agus D, MacVicar G, Wang J, MacLean D, Stadler W. Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostate cancer: a phase I/II, open-label study. J Clin Oncol 2010; 28: Abstract 3084.
60. Roessner M, de Wit R, Tannock I etal. Prostate-specific antigen (PSA) response as a surrogate end-point for overall survival (OS): analysis of the TAX 327 study comparing docetaxel plus prednisone with mitoxantrone plus prednisone in advanced prostate cancer. J Clin Oncol 2005; 23: Abstract 4554.
61. Collette L, Burzykowski T, Schroder F. Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials. Eur J Cancer 2006; 42: 1344-50.
62. Danila D, Heller G, Gignac G etal. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 2007; 13: 7053-8.
63. Zhao L, Lee B, Brown D etal. Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Res 2009; 69: 7696-703.